NasdaqGS - Nasdaq Real Time Price USD

BioNTech SE (BNTX)

87.21

+0.50

(+0.58%)

At close: April 26 at 4:00 PM EDT

87.01

-0.20

(-0.23%)

After hours: April 26 at 7:42 PM EDT

Wall Street plunges after US inflation shock

US stock markets plunged amid fears of stagflation in the American economy, which grew at its slowest pace in nearly two years just as inflation jumped.

The Telegraph 2 days ago

^FTSE

PFE

BHP
Update: GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines

Update: GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines

PREMIUM
MT Newswires 2 days ago

PFE

BNTX
+0.58%
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

Reuters 2 days ago

PFE

GSK

BNTX
+0.58%
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines. GSK said in the lawsuit that Pfizer and BioNTech's Comirnaty vaccines violate the company's patent rights in mRNA-vaccine innovations developed "more than a decade before" the outbreak of the COVID-19 pandemic.

Reuters 2 days ago

GSK

PFE

BNTX
+0.58%
Pfizer vs Moderna battle over COVID vaccine patents begins in UK

Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday. Pfizer and its German partner BioNTech sued Moderna at London's High Court in September 2022, seeking to revoke patents held by Moderna, which hit back days later alleging its patents had been infringed. Moderna says Pfizer and BioNTech copied mRNA advances it had pioneered and patented well before the COVID-19 pandemic began in late 2019.

Reuters 4 days ago

MRNA
+1.69%
PFE

BNTX
+0.58%
25 Richest Billionaires in Healthcare Industry

In this article, we discuss the 25 richest billionaires in healthcare industry. To skip the detailed analysis of the healthcare industry, go directly to the 5 Richest Billionaires in Healthcare Industry. Global Healthcare Industry Outlook and Trends The global healthcare industry is going through a massive transition amid technological advancements, changing patient needs, and demographic […]

Insider Monkey 5 days ago

BNTX
+0.58%
HCA
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this

GlobeNewswire 5 days ago

BNTX
+0.58%
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses up to three years and delayed tumor recurrence in patients with resected pancreatic ductal adenocarcinoma (“PDAC”)A randomized Phase 2 clinical trial with autogene cevumeran in patients with resected PDAC is currently enrolling patients at clinical trial sites in the United States, with addit

GlobeNewswire 20 days ago

BNTX
+0.58%
The 3 Best Bargain Stocks to Buy in Q2 2024

Best bargain stocks to buy is a simple but tricky concept. Whenever shares trade lower than an established multiple, whether that by earnings, sales, book or some other metric, there might be a reason for it. In many cases, it’s not a good one. Let’s face reality here. In the age of the internet, it’s difficult for a well-known publicly traded enterprise to be woefully undervalued. That’s because information is readily available. If the market genuinely believed there was value to be extracted,

InvestorPlace 27 days ago

BNTX
+0.58%
JKS
3 Biotech Stocks to Buy for the Next Bull Run: March 2024

As we step into March 2024, the spotlight is turning towards the biotech sector, with investors searching for biotech stocks to buy. Biotech stocks are ready to soar after a period of under-performance relative to the broader market. With advancements in gene editing, personalized medicine and novel therapeutics, the sector is on the cusp of delivering transformative healthcare solutions. The global biotechnology market is set for remarkable growth. It is forecast to soar from $1 trillion in 202

InvestorPlace last month

BNTX
+0.58%
REGN
-0.84%
VRTX
This Vaccine Maker Sits on Cash Almost Equal to Its Market Value

This biotechnology company has nearly 90% of its market value in cash and investments but is being shunned by investors even as they gravitate to the sector this year. The company is BioNTech (Ticker BNTX). It partnered with Pfizer to produce the leading Covid vaccine, Comirnaty, whose original messenger RNA technology was developed by BioNTech.

Barrons.com last month

BNTX
+0.58%
UPDATE 2-BioNTech gets US agency notice over default on COVID vaccine royalties

BioNTech said on Monday the U.S. National Institutes of Health has sent a notice to the German company regarding default on the payment of royalties and other amounts related to its COVID-19 vaccine. BioNTech, which partnered with U.S. pharma giant Pfizer for its COVID-19 vaccine, however, said it disagreed with the positions being taken by the NIH and intends to defend against all allegations of breach. Spokespersons for the U.S. NIH did not immediately respond to Reuters' request for a comment.

Reuters last month

BNTX
+0.58%
PFE
BioNTech Full Year 2023 Earnings: Misses Expectations

BioNTech ( NASDAQ:BNTX ) Full Year 2023 Results Key Financial Results Revenue: €3.82b (down 78% from FY 2022). Net...

Simply Wall St. last month

BNTX
+0.58%
Earnings Miss: BioNTech SE Missed EPS By 14% And Analysts Are Revising Their Forecasts

BioNTech SE ( NASDAQ:BNTX ) just released its latest annual report and things are not looking great. BioNTech missed...

Simply Wall St. last month

BNTX
+0.58%
BioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Call Transcript

BioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Call Transcript March 20, 2024 BioNTech SE misses on earnings expectations. Reported EPS is $1.9 EPS, expectations were $2.64. BNTX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the BioNTech’s Fourth Quarter […]

Insider Monkey last month

BNTX
+0.58%
Q4 2023 BioNTech SE Earnings Call

Q4 2023 BioNTech SE Earnings Call

Thomson Reuters StreetEvents last month

BNTX
+0.58%
PFE

AUTL
BioNTech Hits Three-Year Low As Covid Vaccine Sales Plummet 65%, Missing Forecasts

BioNTech stock tumbled Wednesday after the Covid vaccine maker reported light fourth-quarter sales and profit.

Investor's Business Daily last month

BNTX
+0.58%
BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials

BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer Inc (NYSE: PFE) for saving the world from the pandemic with their jointly developed vaccine. On Wednesday, BioNTech reported a revenue and earnings drop as it continues its shift towards cancer drug development, much like its peer Pfizer who also turned to oncology in response to falling sales. In January, Pfizer revealed that sales of the COVID shot plummeted 54% to $5.36 billion. Upon its latest repo

Benzinga last month

BNTX
+0.58%
PFE
BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript

BNTX earnings call for the period ending December 31, 2023.

Motley Fool last month

BNTX
+0.58%
BioNTech expects more than 10 bln eur peak sales from cancer drug pipeline

BioNTech estimates that its 10 most advanced cancer treatment candidates could generate combined peak sales of more than 10 billion euros ($10.9 billion), after reporting an ongoing decline in its COVID-19 vaccine business. "The peak sales estimate for that collection of assets is actually well over 10 billion euros in our long term estimates," BioNTech's head of strategy, Ryan Richardson, said in analyst call on Wednesday after the release of 2023 results. He would not be drawn on a combined sales estimate for the year 2030, when asked by an analyst.

Reuters last month

BNTX
+0.58%

Performance Overview

Return	BNTX	MSCI WORLD
YTD	-17.37%	+5.23%
1-Year	-21.94%	+18.44%
3-Year	-48.87%	+12.98%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioNTech SE (BNTX)

Wall Street plunges after US inflation shock

Update: GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines

UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

Pfizer vs Moderna battle over COVID vaccine patents begins in UK

25 Richest Billionaires in Healthcare Industry

BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

The 3 Best Bargain Stocks to Buy in Q2 2024

3 Biotech Stocks to Buy for the Next Bull Run: March 2024

This Vaccine Maker Sits on Cash Almost Equal to Its Market Value

UPDATE 2-BioNTech gets US agency notice over default on COVID vaccine royalties

BioNTech Full Year 2023 Earnings: Misses Expectations

Earnings Miss: BioNTech SE Missed EPS By 14% And Analysts Are Revising Their Forecasts

BioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Call Transcript

Q4 2023 BioNTech SE Earnings Call

BioNTech Hits Three-Year Low As Covid Vaccine Sales Plummet 65%, Missing Forecasts

BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials

BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript

BioNTech expects more than 10 bln eur peak sales from cancer drug pipeline

Performance Overview